🔥 Monday 31 August 2026 Mon, 31 Aug 2026

Pengana International Equities (ASX: PIA) posted a sharp 82% plunge in net profit for FY26, triggering a strategic board reshuffle and a capital management package including a special dividend and buy-back proposal.

Infotrust Ltd (ASX: ITS) reported a 9.8% rise in FY26 revenue to $64.1 million, powered by a strategic pivot to cyber security. The company exited its Cloud segment, repaid all bank debt, and acquired Catalyst Cyber to boost federal market presence, positioning for profitable growth in FY27.

Recce Pharmaceuticals narrowed its operating loss to AUD 15 million in FY26, progressing Phase 3 trials for its anti-infective RECCE 327 and securing key patents and commercial partnerships.

Larvotto Resources has kicked off gold and antimony production at its Hillgrove Mine, marking a major milestone as it becomes Australia’s largest antimony producer and a key global supplier amid tightening critical mineral markets.

Atomos Ltd posted a 22.5% revenue increase to $40 million for FY26, returning to profitability with a $0.9 million net profit after tax, buoyed by cost cuts and the strategic acquisition of Flanders Scientific.

Orpheus Uranium Limited (ASX: ORP) reported a $1.8 million loss for FY2026 while bolstering its uranium project portfolio across Australia and raising over $8.6 million in capital. The company is positioning itself to benefit from rising uranium demand driven by global energy transitions.

Ceryvyn Therapeutics (ASX:CYV) swung to a A$330 million profit in FY26, driven by a one-off gain from settling a major funding agreement. The company pivots to rare lung disease drug development with a lean cash runway.

WestStar Industrial reversed a prior-year loss to report a $3.8 million net profit for FY26, driven by a 258% revenue jump at SIMPEC and strong contract wins.

Harris Technology Group Limited posted a 24% rise in revenue to $17.16 million in FY26, cutting its net loss by 87% to just $121,000 and turning operating cash flow positive for the first time.

Benz Mining has unveiled significant drilling success at its Glenburgh Gold Project, alongside a robust capital raise boosting cash reserves to CAD 81.2 million. The company advances pre-development work and maintains steady resource estimates at its Canadian Eastmain Project.

Wellnex Life reported a 5.1% revenue increase to $24.8 million and slashed its net loss by 70.8% to $4.5 million in FY26, while preparing to sell its Pain Away brand for nearly $20 million to shore up its balance sheet.

La Trobe Private Credit Fund (ASX: LF1) posted a $16 million profit in its inaugural financial year, maintaining steady monthly distributions and executing significant capital management initiatives.

Xenitra Limited’s FY2026 results reveal a deeper loss and halved revenue, but a sharper focus on higher-margin OTC medicines and tokenisation signals a turning point in its turnaround.

Carbonxt Group Limited (ASX:CG1) reduced its FY26 loss by nearly a third, achieved positive operating cash flow for the first time, and pushed forward with commissioning its Kentucky activated carbon facility despite delays. A post-year-end two-stage debt restructuring aims to underpin FY27 growth.

Argent BioPharma (ASX: RGT) narrowed its net loss to $7.7 million for FY2026, while striking a pivotal global licensing agreement for its CannEpil® epilepsy therapy that extinguishes $7.4 million in secured debt and secures ongoing royalties.

TPC Consolidated reported a modest 1.7% revenue rise to $196.3 million for FY26 alongside a striking 1247% jump in net profit, buoyed by calmer wholesale energy prices and strategic investments in battery storage and AI.

Stakk Limited posted a dramatic 1,098% jump in FY2026 revenue to A$14.89 million and achieved its first operating profit of A$1.07 million. The statutory loss widened due to acquisition and legacy wind-down costs, while a $27 million placement funds its pending ParaScript acquisition.

Metal Powder Works Limited reported a doubling of its annual loss to $12.38 million despite a 40% revenue increase, while fast-tracking its production capacity to 800 metric tonnes by mid-2027.

AJ Lucas delivered a $28.5 million profit in FY2026, reversing a prior loss, driven by a $25.9 million UK settlement and disciplined debt reduction despite subdued Australian drilling activity.

Vmoto Limited posted its strongest half-year sales ever with $35.7 million revenue and a 140% surge in unit sales, underpinned by new global partnerships and international market growth.

Oliver's Real Food swung to a statutory profit of $598k in FY2026, reversing a $2.91 million loss a year earlier, driven by store closures and cost discipline. Despite an 8% revenue drop, EBITDAI surged 36.8%, and the company kicked off FY27 with encouraging sales and earnings growth.

AF Legal Group Ltd reported a 30% surge in revenue to $35.9 million and a 354% increase in profit after tax attributable to owners in FY26, driven by strategic investments in technology and management restructuring.

Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.

BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.